Phase 3 monotherapy available Feature Expected GI burden Cagrilintide + Retatrutide Very high CagriSema (Cag + Sema) High Retatrutide Alone High Feature Dysesthesia risk Cagrilintide + Retatrutide Yes (retatrutide component) CagriSema (Cag + Sema) No Retatrutide Alone Yes Feature Injections per week Cagrilintide + Retatrutide 2 (separate) or 1 (pre-blend) CagriSema (Cag + Sema) 1 or 2 Retatrutide Alone 1 Feature Regulatory status Cagrilintide + Retatrutide Neither approved
However, the limited translation of these extracts into effective response in clinical trials, underlined further elucidation of potential candidates
Inositols and metabolic disorders: From farm to bedside
Of interest here is the recent description that AMP-activated protein kinase (AMPK), a hypothalamic enzymatic complex involved in the hypothalamic control of energy and metabolic homeostasis, and activated by ghrelin, participates in the control of GH secretion, as its blocking or its functional impairment inhibits ghrelin- or GHRH-induced GH secretion, most likely by increasing SS tone (88)
Last, remember that research is still developing
